Sucampo Pharma (SCMP) Tops Q2 EPS by 1c; Reiterates 2017 Guidance

Sucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.28, $0.01 better than the analyst estimate of $0.27. Revenue for the quarter came in at $59.9 million versus the consensus estimate of $56.43 million.

Guidance

Sucampo today reiterated its guidance for the full year ending December 31, 2017. Sucampo expects total revenue of $220.0 million to $230.0 million, adjusted net income of $56.0 million to $66.0 million, adjusted EPS of $1.00 to $1.10, adjusted EBITDA of $109.0 million to $119.0 million and free cash flow of $86.0 million to $96.0 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance